Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma

Overview of attention for article published in Frontiers in oncology, June 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Readers on

mendeley: 17 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 12,636 followers.

Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma #FrontOncol https://t.co/aoDhbs3pbS

27 Jun 2022

Reply Repost Favourite

New research: Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma: Neuroblastoma (NB) is the most common extracranial malignant tumor in children. Although the… https://t.co/38

10 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.